# A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

> **NCT03618797** · PHASE3 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 347 (actual)

## Conditions studied

- Complex-dyslipidemia

## Interventions

- **DRUG:** HL-PIF cap.160/2mg + Placebo
- **DRUG:** Livalo tab. 2mg + Placebo

## Key facts

- **NCT ID:** NCT03618797
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-01
- **Final completion:** 2018-05
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618797, "A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*